Related Experiment Video
Updated: Jul 13, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
Tobacco dependence and the nicotine patch. Clinical guidelines for effective use
M C Fiore1, D E Jorenby, T B Baker
1Center for Tobacco Research and Intervention, University of Wisconsin Medical School, Madison 53706.
Transdermal nicotine patches effectively aid smoking cessation, doubling quit rates compared to placebo. Success is enhanced by counseling, with 6-8 weeks of therapy potentially sufficient for most tobacco users.
Area of Science:
- Pharmacology
- Addiction Medicine
- Public Health
Background:
- Tobacco dependence is a significant public health issue.
- Nicotine replacement therapy (NRT) is a widely used smoking cessation aid.
- Transdermal nicotine patches offer a method for delivering nicotine without combustion products.
Purpose of the Study:
- To comprehensively review transdermal nicotine treatment for tobacco dependence.
- To derive recommendations from existing research literature.
- To assess the efficacy and influencing factors of nicotine patch therapy.
Main Methods:
- Systematic review of English-language clinical trials.
- Inclusion of placebo-controlled, double-blind studies (11 studies).
- Focus on trials with at least 6 months follow-up and biochemical verification of smoking status.
Main Results:
- Nicotine patches yielded end-of-treatment cessation rates of 18-77%, approximately double placebo rates.
- Six-month abstinence rates were 22-42% for nicotine patches versus 5-28% for placebo.
- Patches reduced craving and negative moods but not hunger or weight gain; adjuvant counseling is crucial.
Conclusions:
- Transdermal nicotine patches are effective in treating tobacco dependence.
- Success rates are highly variable and influenced by counseling intensity.
- Further research is needed on optimal duration, dosage, and individualization of therapy.
Related Concept Videos
Drug Dependence
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...

